A client needed the real-world treatment landscape for ATTR amyloidosis across the US and EU: how often treaters encounter it, the diagnostic tools relied on to confirm it, the symptoms that prompt it as a differential, the management challenges, and the factors driving treatment decisions.
We fielded 50 quantitative surveys of 30 minutes with cardiologists and neurologists — the two specialties that actually see these patients — on our hybrid CATI/online methodology.
Recruitment to final raw data, delivered in Excel and SPSS: one and a half weeks.
Rare disease research is where network depth shows. Talk to our team.